CHL

Crothall Healthcare and Ascendco Health Partner to Revolutionize Surgical Instrument Tracking and Quality in Sterile Processing

Retrieved on: 
星期四, 五月 9, 2024
Managed Care, Software, Other Health, Data Management, Technology, Medical Devices, Hospitals, Health Technology, Surgery, Biotechnology, Medical Supplies, Practice Management, Health, Safety, Risk, CST, CER, Partnership, SPD, IUSS, Decontamination, Patient safety, CIS, CHL, Knowledge, Overalls, Medical device

In a move poised to significantly elevate standards within Sterile Processing, Crothall Healthcare (Crothall), a leading provider of sterile processing and support services, and Ascendco Health (Ascendco), a leading health technology innovator, today announced a groundbreaking partnership that will bring forth a new era for instrument tracking and overall sterile processing quality within healthcare facilities across the nation.

Key Points: 
  • In a move poised to significantly elevate standards within Sterile Processing, Crothall Healthcare (Crothall), a leading provider of sterile processing and support services, and Ascendco Health (Ascendco), a leading health technology innovator, today announced a groundbreaking partnership that will bring forth a new era for instrument tracking and overall sterile processing quality within healthcare facilities across the nation.
  • "This partnership represents a significant leap forward for Sterile Processing," expressed Afif Escheik, BA, a-IPC, CHL, CER, CIS, CRCST, CST, Regional Director of Operations at Crothall Healthcare.
  • "We are delighted to join forces with Crothall Healthcare, a renowned leader in the sterile processing domain," said Brian Reed, CEO of Ascendco Health.
  • This will ensure that sterile processing departments across the country can operate at the peak of efficiency and quality, ultimately safeguarding patient well-being.

BioSteel Announces Launch of BioSteel Sports Academy

Retrieved on: 
星期四, 四月 18, 2024
BioSteel, T1EHL, Organization, OBA, Ontario Secondary School Diploma, Ice, Hockey Canada, School, Partnership, AAA, Culture, CHL, Leamington Flyers, Athlete, NHL, Hockey, OMHA, Student, OSSD, Growth, NCAA

BioSteel launches BioSteel Sports Academy, transitioning from NHL hydration partner to focus on empowering athletes worldwide.

Key Points: 
  • BioSteel launches BioSteel Sports Academy, transitioning from NHL hydration partner to focus on empowering athletes worldwide.
  • Formerly A21 Academy, the rebranded academy offers Ontario Private School courses (grades 6-12), focusing on university prep through the Hockey Canada Accredited School program.
  • In a bold step towards the future, Biosteel unveils the **BioSteel Sports Academy ( https://biosteelsportsacademy.com )**.
  • With the launch of BioSteel Sports Academy, partnership with PowerTech and our renewed focus on grassroots initiatives and influencer marketing, we're taking that vision to new heights.

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

Retrieved on: 
星期四, 三月 7, 2024
Regeneration, AI, MD, Stem cell, Ageing, Drug development, National University Health System, Telomere, CHL, HUVEC, Conference, Longevity, B cell, NUHS, MSC, Poster, TELO, Research, Pharmaceutical industry

The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.

Key Points: 
  • The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.
  • The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions.
  • The collaboration is expected to help accelerate the development of Telomir-1, improve its safety profile, and significantly reduce the research and development costs of Telomir’s drug development program.
  • To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

Summary of opinion: Keytruda, 22/02/2024 Positive

Retrieved on: 
星期日, 三月 10, 2024
Carboplatin, GEJ, Hodgkin lymphoma, Patient, HNSCC, Cervical cancer, Ageing, CHL, Colorectal cancer, ALK, BTC, Head, Large intestine, Neck, Committee, Recurrence, IIC, Marketing, RCC, Renal cell carcinoma, Cancer, TPS, CHMP, Trastuzumab, TNBC, Paclitaxel, ASCT, Axitinib, Transitional epithelium, NSCLC, Lung cancer, European Commission, EGFR, Cholangiocarcinoma, Medication package insert, CRC, Neoplasm, Radiation, Cisplatin, Civil service commission, Pembrolizumab, Endometrial cancer, Nephrectomy, Platinum, MSI-H, Pemetrexed, Bevacizumab, Risk, Transitional cell carcinoma, CPS, PD-L1

Summary of opinion: Keytruda, 22/02/2024 Positive

Key Points: 


Summary of opinion: Keytruda, 22/02/2024 Positive

Days Inns - Canada Teams Up with Curling Canada and the Canadian Hockey League to Launch Winning National Partnerships

Retrieved on: 
星期二, 一月 23, 2024
Days Inn, CHL, Dow, Partnership, Athlete, BKT, DAYS, Hockey, Days Inns – Canada, AB, Curling Canada, Season, Travel + Leisure Co., Marketing, Kubota, Hotel

"We are thrilled to once again be working with Curling Canada and the Canadian Hockey League," said Ally Wesson, VP of Marketing at Days Inns - Canada.

Key Points: 
  • "We are thrilled to once again be working with Curling Canada and the Canadian Hockey League," said Ally Wesson, VP of Marketing at Days Inns - Canada.
  • "Curling and hockey are some of Canadians' favourite winter activities, and it's an honour for Days Inn to be part of these vibrant sports.
  • Days Inns - Canada will join other recognized brands as a national partner for the 2024 Scotties Tournament of Hearts , the 2024 Montana's Brier and 2024 BKT World Women's Curling Championship .
  • "Curling Canada is excited to have Days Inns - Canada back for our Season of Champions Events ," said Nolan Thiessen, CEO, Curling Canada.

ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

Retrieved on: 
星期一, 十二月 11, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Doxorubicin, Safety, Toxicity, Rollcage Stage II, AVD, Progression-free survival, Progressive multifocal leukoencephalopathy, ADC, Febrile neutropenia, Brentuximab vedotin, Patient, Research and development, PFS, Bleomycin, DOR, PML, Hodgkin lymphoma, PD-1, CHL, Lymphoma, Vinblastine, Dacarbazine, Development, Nivolumab, Survival, Massachusetts General Hospital, ADCETRIS, Immunotherapy, Society, Inc., Hospital, Ima Hogg, Pharmaceutical industry, Vaccine, Medical device, Birth control, Seagen

This is the first time 12-month PFS results were presented for the treatment combination, which avoids use of vinblastine and bleomycin in patients with early stage cHL.

Key Points: 
  • This is the first time 12-month PFS results were presented for the treatment combination, which avoids use of vinblastine and bleomycin in patients with early stage cHL.
  • The PFS rate was 100% (95% CI: 100, 100) at 12 months and 97% (95% CI: 90.3, 99.1) at 18 months.
  • Among 56 efficacy-evaluable patients, 95% had an OR (95% CI: 85.1, 98.9) and 89% had a CR (95% CI: 78.1, 96.0).
  • The estimated PFS rate at 24 months was 88% (95% CI: 75.7, 94.6), with a median follow-up of 24.2 months (95% CI: 23.4, 26.9).

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Expansive Portfolio of Hematology/Oncology Data at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
星期二, 十一月 28, 2023
Acute promyelocytic leukemia, ATRA, NCI-designated Cancer Center, Research, Safety, RWJBarnabas Health, Toxicity, Progression-free survival, National Cancer Institute, Bone marrow, Ageing, ASH, Consortium, EFS, Clinical trial, Leukemia, Holism, Patient, PFS, Probability, APL, SWOG, Hodgkin lymphoma, Exposition, Multiple myeloma, CHL, Prognosis, Abstract, Diagnosis, Cancer, Death, Partnership, Arsenic trioxide, Society, Cooper University Hospital, Health, Lymphoma, Pharmaceutical industry, Medical device, MD

NEW BRUNSWICK, N.J., Nov. 28, 2023 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present an extensive array of hematology/oncology data from their clinical research program at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in San Diego, California (and virtually) from December 9-12, 2023. A total of 36 abstracts have been accepted, comprising clinical data and analyses that advance the understanding, treatment, and prognosis of blood cancers such as lymphoma, leukemia, and myeloma. Rutgers Cancer Institute of New Jersey, in partnership with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.

Key Points: 
  • Rutgers Cancer Institute of New Jersey, in partnership with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.
  • "As the leading cancer program in the state, our commitment to advancing oncology care is unwavering.
  • The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS), event-free survival (EFS), and safety.
  • The full list of presentations at this year's ASH Annual Meeting and Exposition follows:

New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate

Retrieved on: 
星期四, 十一月 2, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Brentuximab vedotin, Lymphoma, Society, Development, ASH, CHL, Hodgkin lymphoma, ADC, Inc., Research and development, Immunotherapy, Exposition, ADCETRIS, Patient, Pharmaceutical industry, Seagen

The data will be featured in two oral presentations at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 9-12, 2023 in San Diego.

Key Points: 
  • The data will be featured in two oral presentations at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 9-12, 2023 in San Diego.
  • The ongoing Phase 2 clinical trial, SGN35-027, is evaluating ADCETRIS in combination with immunotherapy and chemotherapy.
  • In addition, pre-clinical data will be presented for a next-generation novel CD30-directed antibody-drug conjugate (ADC), SGN-35C, that uses a topoisomerase I inhibitor payload.
  • ADCETRIS is a proven foundation of care for certain CD30-expressing lymphomas with more than 120,000 patients treated globally across seven indications.

Octagon Credit Investors names Gretchen Lam as Chief Executive Officer

Retrieved on: 
星期二, 十月 17, 2023
Asset Management, Professional Services, Finance, Generali, Credit, Intelligence, Assicurazioni Generali, Babson College, CHL, CLO, Lisp (programming language), Growth, Conning, News, Temperament, Management, Investment, Octagon

Octagon Credit Investors, LLC (“Octagon”), a leading credit-focused investment manager overseeing $35 billion in total assets, is pleased to announce that Gretchen Lam, Senior Portfolio Manager, will succeed Andrew Gordon as Chief Executive Officer, effective January 1, 2024.

Key Points: 
  • Octagon Credit Investors, LLC (“Octagon”), a leading credit-focused investment manager overseeing $35 billion in total assets, is pleased to announce that Gretchen Lam, Senior Portfolio Manager, will succeed Andrew Gordon as Chief Executive Officer, effective January 1, 2024.
  • Mr. Gordon commented, “Gretchen has been an integral part of Octagon’s success during her 20-plus years at the firm.
  • Gretchen possesses the right balance of intelligence, experience, and temperament to lead Octagon in the years ahead.
  • Ms. Lam said, “I am honored to serve as the next CEO of Octagon at an exciting time in the firm’s growth trajectory.

Kubota Canada and the Canadian Hockey League launch fifth annual Community Hero contest

Retrieved on: 
星期三, 十月 11, 2023
Canadian Hockey League, CHL, Partnership, Organization, Kubota, Volunteering, Marketing, Nursing

PICKERING, ON, Oct. 11, 2023 /CNW/ - Kubota Canada Ltd., in partnership with the Canadian Hockey League (CHL), has launched nominations for its 2023 Community Hero contest .

Key Points: 
  • PICKERING, ON, Oct. 11, 2023 /CNW/ - Kubota Canada Ltd., in partnership with the Canadian Hockey League (CHL), has launched nominations for its 2023 Community Hero contest .
  • Now in its fifth year, Community Hero has brought attention to and commemorated thousands of Canadians who are making a positive impact in their respective communities across the country.
  • Thanks to the efforts of Kubota Canada and the CHL, Canadians will have the opportunity to nominate a hero in their community who deserves the spotlight.
  • Everyone's Community Hero looks different, but nominations are open to anyone making a difference in their community, from dedicated volunteers, healthcare workers to sports coaches and more.